Advertisement
EPRX vs VERA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EPRX is a Buy and VERA is a Hold.
EPRX in upward trend: price rose above 50-day moving average on November 10, 2026
EPRX moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 44 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on EPRX as a result. In 64 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for EPRX just turned positive on November 09, 2026. Looking at past instances where EPRX's MACD turned positive, the stock continued to rise in 27 of 39 cases over the following month. The odds of a continued upward trend are 69%.
Following a +8.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where EPRX advanced for three days, in 101 of 125 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for EPRX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EPRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
EPRX broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EPRX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.213) is normal, around the industry mean (3.498). P/E Ratio (-6.755) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 33 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. EPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for VERA turns negative, indicating new downward trend
VERA saw its Momentum Indicator move below the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned negative. In 85 of the 98 cases, the stock moved further down in the following days. The odds of a decline are at 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for VERA turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 39 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
VERA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VERA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VERA's RSI Indicator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +5.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where VERA advanced for three days, in 238 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
VERA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 196 of 228 cases where VERA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 23 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 57 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.264) is normal, around the industry mean (3.498). P/E Ratio (-5.074) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. VERA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 73 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VERA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
| EPRX | VERA | |
|---|---|---|
| RSI ODDS (%) | N/A | 3 days ago 83% |
| Stochastic ODDS (%) | 3 days ago 68% | 3 days ago 86% |
| Momentum ODDS (%) | 3 days ago 75% | 3 days ago 87% |
| MACD ODDS (%) | 3 days ago 69% | 3 days ago 85% |
| TrendWeek ODDS (%) | 3 days ago 54% | 3 days ago 83% |
| TrendMonth ODDS (%) | 3 days ago 55% | 3 days ago 84% |
| Advances ODDS (%) | 5 days ago 81% | 12 days ago 83% |
| Declines ODDS (%) | 11 days ago 74% | 3 days ago 83% |
| BollingerBands ODDS (%) | 3 days ago 76% | 3 days ago 78% |
| Aroon ODDS (%) | 3 days ago 46% | 3 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EPRX’s FA Score shows that 2 FA rating(s) are green while VERA’s FA Score has 1 green FA rating(s).
- EPRX’s FA Score: 2 green, 3 red.
- VERA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EPRX’s TA Score shows that 4 TA indicator(s) are bullish while VERA’s TA Score has 5 bullish TA indicator(s).
- EPRX’s TA Score: 4 bullish, 5 bearish.
- VERA’s TA Score: 5 bullish, 4 bearish.
Price Growth
EPRX (@Biotechnology) experienced а +18.29% price change this week, while VERA (@Biotechnology) price change was -5.66% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
EPRX is expected to report earnings on Mar 30, 2027.
VERA is expected to report earnings on Mar 25, 2027.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EPRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, EPRX has been loosely correlated with ASMB. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if EPRX jumps, then ASMB could also see price increases.
| Ticker / NAME | Correlation To EPRX | 1D Price Change % | ||
|---|---|---|---|---|
| EPRX | 100% | +4.35% | ||
| ASMB - EPRX | 38% Loosely correlated | +4.66% | ||
| TARS - EPRX | 37% Loosely correlated | +4.41% | ||
| NAMS - EPRX | 36% Loosely correlated | +0.85% | ||
| EDIT - EPRX | 34% Loosely correlated | +1.40% | ||
| VERA - EPRX | 34% Loosely correlated | -3.24% | ||
More | ||||
VERA and
Correlation & Price change
A.I.dvisor indicates that over the last year, VERA has been loosely correlated with MGTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if VERA jumps, then MGTX could also see price increases.
| Ticker / NAME | Correlation To VERA | 1D Price Change % | ||
|---|---|---|---|---|
| VERA | 100% | -3.24% | ||
| MGTX - VERA | 43% Loosely correlated | +4.44% | ||
| VKTX - VERA | 43% Loosely correlated | +5.95% | ||
| SRRK - VERA | 42% Loosely correlated | +0.10% | ||
| NAMS - VERA | 41% Loosely correlated | +0.85% | ||
| VYGR - VERA | 41% Loosely correlated | +1.76% | ||
More | ||||